BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eisai Company, Ltd. (ESALY.PK) Opens New Solid Dose Global Manufacturing Line for Antiepileptic Agent Fycompa® at Its Production Plant in Hatfield, U.K.


9/27/2012 4:17:22 PM

Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.K. manufacturing subsidiary Eisai Manufacturing Ltd. (EML) situated within the company's European Knowledge Centre (EKC), has received a license (marketing authorization type II variation: addition of manufacturing site) from the European regulatory authorities for solid dose manufacturing of the antiepileptic agent Fycompa(R) (perampanel), a first-in-class AMPA receptor antagonist discovered and developed in-house, at its Hatfield production plant. Eisai celebrated this occasion with a ceremony to mark the official opening of a new Fycompa manufacturing line.

Read at JCN Newswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->